EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Pluri Inc. (PLUR) fair value: what the stock is really worth

We calculate from audited financials what Pluri Inc. is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jun 23, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US72942G2030

PI Pluri Inc. logo Thin data Jun 23, 2026

Pluri Inc.

PLUR · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.3655 · Strongly overvalued (−66%)
!Quality 21/100
!Mixed Growth (revenue 5y +125.3 %/yr)
!Negative equity (buybacks among others) · negative free cash flow
!Trails peers (0/5)
!Narrow moat 21/100
!Evidence only low, so the estimate is less certain
Watch Pluri Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$32.88 $1.06 Fair Value $0.3655 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 23, 2026.

How to read this chart

60‑month range $1.06 – $32.88 · fair‑value band $0.2805 – $0.4590 · the $1.06 price screens above the $0.3655 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jun 23, 2026.

Follow Pluri in your weekly email

Every Wednesday you see whether Pluri is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform.

Show more

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Stock analysis

Pluri Inc. (PLUR) currently trades at $1.06, while our model-based Fair Value estimate is $0.3655, implying the stock looks roughly 190.0% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 3 models at a data quality of 80/100, which puts the evidence level at low.

Scenario range: $0.2805 (bear) to $0.4590 (bull), the price of $1.06 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 21/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Pluri Inc. reported revenue of $1.3M in FY2025 versus $0 in FY2021. Reported net income was −$22.6M in FY2025.

Key figures

Market cap $21.8M · P/S ratio 20.2 · EPS (TTM) $−2.90 · Return on equity −1,022% · Return on assets (EBIT) −56.5% · Operating margin −3,914% · Revenue (TTM) $1.1M · Revenue growth (YoY) −60.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).

What moves the price

The share trades about 77% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −66%, PLUR screens richer than that median.

Notify me when PLUR reaches fair value

Put PLUR on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 21/100

Of which business quality 20 · Market factors (momentum, volatility) 13

Profitability 1
Margins and returns on capital today
Quality Growth 53
Are margins and returns improving?
Cashflow 7
Earnings quality: real cash, not paper profit
Fin. Strength 17
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 45
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 28/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+309.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+78.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+125.3%
Start year 2020 (pandemic). Over 10 years: +13.4% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−128,156.5% (2020) → −1,659.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PLUR screens 190% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Pluri Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks

Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 21 · Bottom 25%
Fair Value upside −66% · Below median
Profitability
Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −51% · Bottom 25%
Growth and dividend
Revenue growth −61% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM) 20.20× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $516.34 $567.97 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Pluri Inc. · Fair Value
$0.3655 −190%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Pluri Inc. Fair Value". https://www.fairvalue-calculator.com/stock/PLUR

Frequently asked questions

Is Pluri Inc. (PLUR) overvalued or undervalued?
As of Jun 23, 2026, our model estimates a fair value of $0.3655 versus a price of $1.06, about −66% upside (overvalued).
What is the fair value of PLUR?
Our model-based fair value for Pluri Inc. is $0.3655 (as of Jun 23, 2026), built from audited fundamentals. The current price: $1.06.
What is the quality score of PLUR?
Pluri Inc. has a Quality Score of 21/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pluri Inc. (PLUR)?
Our model-based price target is the fair value of $0.3655 (as of Jun 23, 2026) from 3 valuation models. Cautious scenario $0.2805, optimistic scenario $0.4590. It is a calculation from audited fundamentals, not an analyst target.
What is the Pluri Inc. stock forecast for 2026?
Our models put fair value at $0.3655, about −66% upside versus a price of $1.06 (overvalued). Cautious scenario $0.2805, optimistic scenario $0.4590. The calculation is refreshed regularly with new filings.
What is the revenue of Pluri Inc. (PLUR)?
Pluri Inc. reported trailing-twelve-month revenue of about $1.1M (latest available figure, as of Jun 23, 2026).
What is the intrinsic value of Pluri Inc. (PLUR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pluri Inc. it is $0.3655 per share (as of Jun 23, 2026), against a price of $1.06. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Pluri Inc. stock overvalued or undervalued in 2026?
As of Jun 23, 2026, PLUR trades above its calculated fair value: price $1.06, fair value $0.3655, a gap of about −66% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PLUR?
No. The price is what the market pays today ($1.06); the fair value is what the company's own numbers justify ($0.3655). For Pluri Inc. the two are $0.6945 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pluri Inc. worth?
The market values Pluri Inc. at about $21.8M (market capitalisation, as of Jun 23, 2026). Per share that is $1.06; our models calculate a fair value of $0.3655 per share.
What do the bullish and bearish scenarios say about PLUR?
Our models span a range for Pluri Inc.: cautious scenario $0.2805, base $0.3655, optimistic $0.4590 per share (as of Jun 23, 2026, price $1.06). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pluri Inc. (PLUR)?
Balance-sheet figures for Pluri Inc. (as of Jun 23, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 21/100, which measures business quality independently of the share price.
How far is PLUR from its 52-week high?
Pluri Inc. trades at $1.06, about 77% below its 52-week high of $4.70 and at the low of $1.06 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.3655 is for.
Which stocks are comparable to Pluri Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pluri Inc. stock attractive at the current price?
The data as of Jun 23, 2026: price $1.06, calculated fair value $0.3655 (−66%), Quality Score 21/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PLUR calculated?
We run Pluri Inc. through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.3655, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Pluri Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pluri Inc. (PLUR)?
The closing price on Sep 23, 2026 was $1.06. Our model-based fair value is $0.3655, about −66% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pluri Inc. right now?
The price sits above even our optimistic bull case ($0.4590). The favourable scenario is already priced in. Weak quality (21/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Pluri Inc.

How large is the market capitalisation of Pluri Inc. (PLUR)?
The market capitalisation of Pluri Inc. is $21.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pluri Inc. (PLUR)?
The price-to-sales ratio of Pluri Inc. is 20.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pluri Inc. (PLUR)?
Earnings per share at Pluri Inc. are $−2.90. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Pluri Inc. (PLUR)?
The return on equity (ROE) of Pluri Inc. is −1,022% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pluri Inc. (PLUR)?
On an EBIT basis the return on assets of Pluri Inc. is −56.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pluri Inc. (PLUR)?
The operating margin of Pluri Inc. is −3,914% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pluri Inc. (PLUR)?
Revenue at Pluri Inc. is growing −60.9% versus a year earlier (3y avg +78.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Pluri Inc. (PLUR) generate?
The free cash flow of Pluri Inc. is −$19.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Pluri Inc. (PLUR) carry?
The net debt of Pluri Inc. is $28.2M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Pluri Inc. in the live analysis

One click puts Pluri Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.